While certain peptides (such as semaglutide) are FDA-approved for specific medical indications, others may be used off-label based on individualized patient needs
gains with your clinician
Dr Malige pointed to patent timelines and said, Semaglutide will go out of patency in March 2026 after that, leading Indian pharmaceutical companies will manufacture and market semaglutide, which will bring down the cost significantly. $499 in the U.S., 17,000 in India: The Cost of Chasing the Skinny Jab Dream Patent expiry matters
Project n TIP.A2.25.014
We focus on long-term success by addressing the underlying causes of weight gain, such as metabolism and hunger regulation, rather than relying on short-term diet trends
Retatrutide works by enhancing insulin secretion, suppressing appetite, slowing gastric emptying, and improving energy metabolism